Isoliquiritigenin protected against cigarette-smoke-induced chronic obstructive pulmonary disease (COPD) via suppression of inflammation and oxidative stress by targeting the Nrf2 and NF-κB signaling pathways [64]. The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.